Journal
NUTRITION REVIEWS
Volume 72, Issue 1, Pages 18-29Publisher
OXFORD UNIV PRESS INC
DOI: 10.1111/nure.12084
Keywords
cardiovascular health; low-density lipoprotein; probiotic; safety; therapeutic diets
Categories
Funding
- Micropharma, Montreal, Canada
Ask authors/readers for more resources
The objectives of this article are to review clinical trials that have examined the effects of probiotics on low-density lipoprotein cholesterol (LDL-C) and to assess the potential of probiotic intake as a therapeutic lifestyle change (TLC) dietary option. Twenty-six clinical studies and two meta-analyses are reviewed. Significant LDL-C reductions were observed for four probiotic strains: LactobacillusreuteriNCIMB 30242, Enterococcusfaecium, and the combination of LactobacillusacidophilusLa5 and BifidobacteriumlactisBb12. Two synbiotics, L.acidophilusCHO-220 plus inulin and L.acidophilus plus fructo-oligosaccharides, also decreased LDL-C. Of the probiotics examined, L.reuteriNCIMB 30242 was found to best meet TLC dietary requirements by 1) significantly reducing LDL-C and total cholesterol, with robustness similar to that of existing TLC dietary options, 2) improving other coronary heart disease risk factors, such as inflammatory biomarkers, and 3) having generally recognized as safe (GRAS) status. Based on these results, the probiotic L.reuteriNCIMB 30242 is a viable candidate both for future TLC dietary studies and as a potential option for inclusion in TLC dietary recommendations. (C) 2013 International Life Sciences Institute
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available